Form 4: Avalon Ventures and Jay Lichter Report Janux Therapeutics Stock Sales
SEC Form 4 Filing
Avalon Ventures XI, L.P., Avalon BioVentures I, LP, Avalon BioVentures SPV I, L.P., and Jay Lichter report sales and option exercises of Janux Therapeutics, Inc. stock between October 16 and October 18, 2024.
Summary
- Avalon Ventures XI, L.P., Avalon BioVentures I, LP, Avalon BioVentures SPV I, L.P., and Jay Lichter filed a Form 4 detailing changes in beneficial ownership of Janux Therapeutics, Inc. stock.
- The transactions include sales of common stock at prices ranging from $44.75 to $51.97.
- The transactions also include the exercise of stock options at prices of $10.73, $13.22, $17 and $39.80.
- The sales were executed between October 16 and October 18, 2024.
- A portion of the shares were sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024, which closed on October 18, 2024.
Sentiment
Score: 4
Explanation: The sentiment is neutral to slightly negative. While the filing itself is a standard regulatory requirement, the sales of stock by a major shareholder could be interpreted negatively by the market.
Risks
- Large sales by significant shareholders like Avalon Ventures could create downward pressure on the stock price.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders and major shareholders, providing transparency to the market.
Stakeholder Impact
- Shareholders may react to the news of stock sales by major holders.
- The sales could influence the market's perception of the company's value.
Key Dates
| Date | Description |
|---|---|
| September 12, 2024 | Date of the stock purchase agreement for a private transaction. |
| October 16, 2024 | Date of earliest transaction reported. |
| October 17, 2024 | Date of transactions reported. |
| October 18, 2024 | Date of closing of the private transaction and final transactions reported. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.